



Corrigendum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek

Dong Min Shin¹, Jongeun Lee¹, Hyungrye Noh¹, Donghwi Jang¹, Se Jin Oh¹, Ji Hye Park¹, Jong Hee Lee^{1,2}

¹Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, ²Department of Medical Device Management & Research, The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea

Annals of Dermatology 2022;34(6):442-450

<https://doi.org/10.5021/ad.21.316>

The botulinum toxin type A 150 kD neurotoxin (Coretox; Medytox, Seoul, Korea) was used in this clinical study. It has not been approved as “incobotulinum toxin A” by FDA yet and therefore, the term “incobotulinum toxin A (previously abbreviated as BTXAi in the manuscript)” is changed into “botulinum toxin A 150 kD neurotoxin (abbreviated as BTXA150).”

The original article has been modified.

We sincerely apologize for any confusions that we may have caused.

